

MATERIALS LICENSE

Amendment No. 02

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

302668

Licensee		In accordance with the letter dated April 28, 1997	
1. Cardiovascular Medicine Associates		3. License Number 34-26706-01 is amended in its entirety as follows:	
2. 7255 Old Oak Boulevard, Suite C-208 Middleburg Heights, OH 44130		4. Expiration Date April 30, 2001	
		5. Docket or Reference No. 030-34091	
6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A. Any byproduct material identified in 10 CFR 35.200	A. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding generators, xenon, and radioactive aerosols) limited to cardiovascular clinical procedures.	A. As needed	
9. Authorized Use:			
A. Medical use described in 10 CFR 35.200 (excluding generators, xenon, and radioactive aerosols) limited to cardiovascular clinical procedures.			

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at
7225 Old Oak Boulevard, Suite A-210D, Middleburg Heights, Ohio.
11. Radiation Safety Officer: Sabino D. Velloze, M.D.

230026
9706230108 970610
PDR ADOCK 03034091
C PDR



COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

34-26706-01

Docket or Reference Number

030-34091

Amendment No. 02

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

- | | |
|----------------------------|---|
| A. Sabino D. Velloze, M.D. | 10 CFR 35.200 (excluding generators, xenon, and radioactive aerosols), limited to cardiovascular clinical procedures. |
| B. Trilok C. Sharma, M.D. | 10 CFR 35.200 (excluding generators, xenon, and radioactive aerosols), limited to cardiovascular clinical procedures. |
| C. Ibrahim Bshara, M.D. | 10 CFR 35.200 (excluding generators, xenon, and radioactive aerosols), limited to cardiovascular clinical procedures. |

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated March 5, 1996; and
B. Letters dated April 1, 1996 and June 17, 1996.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 10 1997

By

Doreen A. Polina
Nuclear Materials Licensing Branch, Region III

COPY

(FOR LFMS USE)
INFORMATION FROM LTS

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

Program Code: 02200
Status Code: 0
Fee Category: 7C
Exp. Date: 20010430
Fee Comments:
Decom Fin Assur Req'd: N

54

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: CARDIOVASCULAR MEDICINE ASSOCIATES
Received Date: 970513
Docket No: 3034091
Control No.: 302668
License No.: 34-26706-01
Action Type: Amendment

2. FEE ATTACHED

Amount: 440
Check No.: 8735

3. COMMENTS

Signed D. Hersey
Date 5-30-97

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered ☒)

1. Fee Category and Amount: 7C

2. Correct Fee Paid. Application may be processed for:

Amendment ☒
Renewal ☐
License ☐

3. OTHER

Signed SC
Date 6/2/97

JUN 05 1997

Log	<u>June 1 III</u>
Remitter	
Check No.	<u>8735</u>
Amount	<u>440</u>
Fee Category	<u>7C</u>
Type of Fee	<u>Am</u>
Date Check Rec'd	<u>6/2/97</u>
Date Completed	
By	<u>SC</u>

1997 JUN - 2 AM 11:45

Cardiovascular Medicine Associates, Inc.

TRILOK C. SHARMA, M.D., F.A.C.C.

SABINO D. VELLOZE, M.D., F.A.C.C.

MARC D. SCHRODE, D.O., F.A.C.C.

(216) 816-2708

OLD OAK MEDICAL PAVILION
7255 OLD OAK BLVD., SUITE C-208
MIDDLEBURG HEIGHTS, OHIO 44130

MEDICAL ARTS CENTER I
6681 RIDGE ROAD, SUITE 210
PARMA, OHIO 44129

April 28, 1997

U.S. Nuclear Regulatory Commission, Region III
Materials Licensing Section
801 Warrenville Road
Lisle, IL 60532-4351

RE: License No. 34-26706-01

Gentlemen:


Please change the above reference license for our facility to reflect the addition of Dr. Ibrahim Bshara and Dr. T. C. Sharma as authorized users. For Dr. Bshara's training and experience, please refer to NRC license No. 34-26649-01; for Dr. Sharma, please refer to attached documentation of training and experience.

Authorization is also requested for the addition of radioactive materials listed in 35.100 and 35.200.

All other conditions of the existing license will remain the same.

Should you have any questions regarding this matter, please feel free to contact me at 216-816-2708.

Sincerely,


Sabino D. Velloze, M.D.
Radiation Safety Officer

SDV:mp

JUN 05 1997

JUN 05 1997

RECEIVED

MAY 13 1997

REGION III

302668
MAY 13 1997

PM:5-6-97

TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER

Trilok C. Sharma, M.D.

2. FOR PHYSICIANS, STATE OR
TERRITORY WHERE LICENSED

Ohio

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION	200 Hour Nuclear Physician Licensing Course held by Associates in Medical Physics, LLC, (formerly NMA Medical Physics Consultation) 5284 Transportation Blvd., Cleveland, OH 44125, on the following dates:	100	
b. RADIATION PROTECTION	March 14-23, 1997 April 18-27, 1997	30	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	"	20	
d. RADIATION BIOLOGY	"	20	
e. RADIOPHARMACEUTICAL CHEMISTRY	"	30	

5. EXPERIENCE WITH RADITATION. (Actual use of Radioisotopes or Equivalent Experience)

RADIOISOTOPE	INCORPORATED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE

PROPOSED PHYSICIAN USER

PRECEPTOR STATEMENT (CONTINUED)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	X	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	X	
I-131	TREATMENT OF THYROID CARCINOMA	X	
	TREATMENT OF HYPERTHYROIDISM	X	
Au-198	INTRACAVITARY TREATMENT	X	
Co-60 or Ca-137	INTERSTITIAL TREATMENT	X	
	INTRACAVITARY TREATMENT	X	
I-125 or Ir-192	INTERSTITIAL TREATMENT	X	
Co-60 or Ca-137	TELETHERAPY TREATMENT	X	
Sr-90	TREATMENT OF EYE DISEASE	X	
	RADIOPHARMACEUTICAL PREPARATION	X	
Mo-99/ Tc-99m	GENERATOR	5	
Sr-113/ In-113m	GENERATOR	X	
Tc-99m	REAGENT KITS	5	
Other	ALUMINA TESTING	5	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION

DATES

CLOCK HOURS OF EXPERIENCE

Associates in Medical Physics, LLC
Cleveland, OhioMarch 14-23, 1997
April 18-27, 19974. THE TRAINING AND EXPERIENCE INDICATED ABOVE
WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

Paul Early

b. NAME OF INSTITUTION

Associates in Medical Physics, LLC


c. MAILING ADDRESS

5284 Transportation Blvd.

d. CITY

Cleveland, Ohio 44125

5. PRECEPTOR'S SIGNATURE



7. PRECEPTOR'S NAME (Please type or print)

Paul Early
President

8. DATE

April 27, 1997

B. MATERIALS LICENSE NUMBER(S)

34-26645-01

ASSOCIATES IN MEDICAL PHYSICS, LLC

THIS CERTIFIES THAT


Trilok C. Sharma, M.D.

HAS SUCCESSFULLY COMPLETED ALL REQUIREMENTS
FOR THE

NUCLEAR PHYSICIAN LICENSING COURSE

AND IS HEREBY AWARDED THIS
CERTIFICATE OF COMPLETION

ON THIS *Twenty-seventh* DAY OF *April*, 1997


DIRECTOR OF TRAINING

MetroHealth Medical Center
2500 MetroHealth Drive, Cleveland, Ohio 44109-1998

216 398-6000

Department of Medicine

October 18, 1996

Nuclear Regulatory Commission
799 Roosevelt Drive
Glen Ellyn, IL 60137

RE: T. C. Sharma, M.D.


To Whom It May Concern:

This letter is confirmation that T.C. Sharma, M.D. has performed more than 1,000 stress myocardial perfusion studies using thallium 201 isotope during the time period from July, 1980 through June, 1983 while he served as a fellow in cardiology as well as an attending cardiologist at MetroHealth Medical Center. He gained clinical experience with thallium exercise SPECT imaging procedures, technetium first pass radionuclide angiography, equilibrium gated radionuclide ventriculography (MUGA Scan), and myocardial infarct imaging.

During his preceptorship, he had supervised examination of patients to determine suitability of nuclear diagnostic studies, selection of the proper isotope, recommendation of the dosage to be used, and was trained to safely handle and administer these radioisotopes to patients during his fellowship tenure.

His training as a cardiology fellow included discussion of the patient's history, their physical exam, results of their stress EKG findings, and the interpretation of their nuclear test results with myself and other members in the Department of Nuclear Cardiology in his training program to confirm accurate diagnoses, and that appropriate patient follow-up was also performed.

Sincerely,



Stefan D. Miron, M.D.
Assistant Professor of Radiology
Case Western Reserve University

U. S. NUCLEAR REGULATORY COMMISSION

[illegible]

PROPOSED PHYSICIAN USER

T. C. Sharma, M.D.

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted to duplicate on separate sheets.) D
P-32 (Sodium)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Cesium)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM		
Am-106	INTRACAVITARY TREATMENT		
C-50	INTERSTITIAL TREATMENT		
Co-137	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Co-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	2	
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	2	
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION	DATES	CLOCK HOURS OF EXPERIENCE
MetroHealth Medical Center 2500 MetroHealth Drive Cleveland, OH, 44109	July 1980 June 1983	1100

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

Stefan D. Miron, M.D.

b. NAME OF INSTITUTION

MetroHealth Medical Center

c. MAILING ADDRESS

2500 MetroHealth Drive

d. CITY

Cleveland, OH 44109

e. TELEPHONE NUMBER

34-03749-10

5. PRECEPTOR'S SIGNATURE

Stefan D. Miron

6. PRECEPTOR'S NAME (Print name or name)

STEFAN D. MIRON, M.D.

7. DATE

10-18-96

Cardiovascular Medicine Associates, Inc.

TRILOK C. SHARMA, M.D., F.A.C.C.

SABINO D. VELLOZE, M.D., F.A.C.C.

MARC D. SCHRODE, D.O., F.A.C.C.

(216) 816-2708

OLD OAK MEDICAL PAVILION
7255 OLD OAK BLVD., SUITE C-208
MIDDLEBURG HEIGHTS, OHIO 44130

MEDICAL ARTS CENTER I
6681 RIDGE ROAD, SUITE 210
PARMA, OHIO 44129

April 28, 1997

U.S. Nuclear Regulatory Commission
Region III
801 Warrenville Road
Lisle, IL 60532-4351


Gentlemen:

Let this letter serve as documentation that T. C. Sharma, M.D. has stayed current in the field of nuclear medicine by the following:

1. Since 1989, Dr. Sharma, a working cardiologist, has participated in the review of nuclear medicine studies that he has ordered at Southwest General Health Center in Middleburg Hts., OH. Dr. Sharma orders approximately 200 nuclear medicine studies per year at this hospital.
2. During 1995, Dr. Sharma participated in the interpretation of nuclear cardiology procedures while associated with a mobile nuclear service. During this association, Dr. Sharma participated in approximately 100 nuclear cardiology procedures.
3. Since we have begun operations at Cardiovascular Medicine Associates, Inc., Dr. Sharma has participated, under my supervision, in all aspects of the nuclear medicine laboratory.

If there are any questions regarding this information, please contact me at 216-816-2708.

Sincerely,


Sabino D. Velloze, M.D.
Radiation Safety Officer

SDV: map

1996 16:07 353486
U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE
SUPPLEMENTARY SHEET

PAGE 2 2 PAGES
License number 34-26649-01
Docket or Reference number 030-33840
Amendment No. 01

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 20545 Center Ridge Road, Suite 110, Rocky River, Ohio and 20525 Center Ridge Road, Suite 148, Rocky River, Ohio.
11. Radiation Safety Officer: Ibrahim Bshara, M.D.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users

Material and Use

Ibrahim Bshara, M.D.

For material listed in 10 CFR 35.100, 35.200 (excluding xenon-133), Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction and strontium-89 for treatment of palliative bone metastases.


13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letters dated April 17, 1995 and May 18, 1995 (excluding the Quality Management Program).
- B. Application dated April 17, 1996.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

5/29/96

By


Nuclear Materials Licensing Branch, Region III

COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301263

Licensee		In accordance with application dated April 17, 1996	
1. Premier Physicians Centers		3. License Number 34-26649-01 is amended in its entirety as follows:	
2. 20525 Center Ridge Road, Suite 148 Rocky River, OH 44116		4. Expiration Date	June 30, 2000
		5. Docket or Reference No.	030-33840
6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding xenon-133)	B. As needed	
C. Iodine-131	C. Any	C. 1 curie	
D. Strontium-89	D. Any	D. As needed	
9. Authorized Use:			
A. Medical use described in 10 CFR 35.100.			
B. Medical use described in 10 CFR 35.200 (excluding xenon-133).			
C. For treatment of hyperthyroidism and cardiac dysfunction.			
D. For treatment of palliative bone metastases.			

COPY

AMW

DATE: 5-19-97

CORRESPONDENCE CLARIFICATION SHEET

REVIEWER: ~~BJ HOLT~~ WATSON
LICENSEE: Cardio med proc.
LICENSE NUMBER: 34-26706-01

The following correspondence has been received from the above licensee and it is not clear what action(s) is(are) required: Please review this correspondence and indicate which of the following applies, and please return to Debbie Hersey, as soon as possible.

- ☐ Additional Information to Control No. _____
Process in as a new action, additional information, and no fee required.
- ☐ Process as new licensing action. Review has already been started on Control No. _____ and this information cannot be combined with current in-house action.
- ☐ Can be combined with Control No. _____. Review has not started.
- ☐ Appears to be information for the license file - file it.
- ☐ Licensee is adding Nuclear Pharmacists.
- ☐ Amendment is necessary _____. Amendment is not necessary _____.
(Information for license file)
- ☒ Licensee is adding authorized users.
- ☒ A check is included ✓. No check is included _____.
Amendment is necessary ✓. Amendment is not necessary _____.
(This is a Notification)
- ☐ Process in as a new licensing action:
A. Amendment _____
B. Renewal _____
C. New License Application _____
- ☐ Other: _____

Thank You For Your Help!!!

10/16/96

JUN 10 1997

Sabino D. Velloze, M.D.
Radiation Safety Officer
Cardiovascular Medicine Associates
7255 Old Oak Boulevard, Suite C-208
Middleburg Heights, OH 44130

Dear Dr. Velloze:

Enclosed is Amendment No. 02 to your NRC Material License No. 34-26706-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
 - a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
 - b. When the mailing address listed on the license changes. (No fee is required if the location of byproduct material remains the same.)
3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

302668

4. Request and obtain a license amendment before you:
 - a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;
 - b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;
 - c. Change Radiation Safety Officers;
 - d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
 - e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
 - f. Change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Statement of Policy and Procedure for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC

S. Velloze

-3-

requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Deborah A. Piskura
Nuclear Materials Licensing Branch

License No.: 34-26706-01
Docket No.: 030-34091

Enclosure: Amendment No. 02

DOCUMENT NAME: M:\03034091.CL7

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII								
NAME	DAPiskura:brt								
DATE	06/10 /97								

OFFICIAL RECORD COPY



UNITED STATES
NUCLEAR REGULATORY COMMISSION

REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

May 30, 1997

Sabino D. Velloze, M.D.
Radiation Safety Officer
Cardiovascular Medicine Associates
7255 Old Oak Boulevard, Suite C-208
Middleburg Heights, OH 44130

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Letter Dated 04/28/97)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

☐ New License ☒ Amendment ☐ Renewal
☐ Termination ☐ Auth User (Amendment not required)
☐ Other _____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.
2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.
3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 302668
License No. 34-26706-01